Third Rock-backed Allena looks to springboard a $92M IPO off of a failed PhIIb
The IPO market for biotech has turned hot. But is it hot enough to get Allena Pharmaceuticals into the public arena?
Three years ago, Allena …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
